Abstract
The novel coronavirus severe acute respiratory syndrome Corona Virus-2 (SARS-CoV- -2) has become a pandemic, as declared by WHO in March 2020 producing deleterious effects on patients worldwide. The angiotensin-converting enzyme-2 (ACE-2) has been recognized as the coreceptor for SARS-CoV-2 infections and may act as a therapeutic step in blocking the enzyme to reduce SARS-CoV-2 expression and further cellular entry. Presently, the role of ACE-2 in coronavirus disease 2019 (COVID-19) infection has been known and the experts have started working on the enzyme ACE-2 for the management and treatment of this pandemic disease. The binding of spike (S) protein of SARS-CoV-2 to these receptors is the most important step and plays a key role in viral replication, thus this enzyme is becoming the doorway for the entry and spread in the human body causing asymptomatic pneumonia and severe of which is leading to death. As no specific method to prevent and treat this disease is available, the use of ACE-2 as a targeting ligand with COVID-19 virus spike protein could be helpful in the proper management of SARS-CoV-2 pneumonia.
Keywords: ACE-2, COVID-19, SARS-CoV-2, TMPRSS2, Furin, ligand.
Coronaviruses
Title:Angiotensin Converting Enzyme-2: A Doorway for SARS-CoV-2
Volume: 2 Issue: 12
Author(s): Vikas Pandey, Indu Lata Kanwar, Tanweer Haider, Vishal Gour, Monika Vishwakarma, Avijit Kumar Bakshi, Ravishankar Yadav and Vandana Soni*
Affiliation:
- Department of Pharmaceutical Sciences, Dr. Harisingh Gour University, Sagar, Madhya Pradesh,India
Keywords: ACE-2, COVID-19, SARS-CoV-2, TMPRSS2, Furin, ligand.
Abstract: The novel coronavirus severe acute respiratory syndrome Corona Virus-2 (SARS-CoV- -2) has become a pandemic, as declared by WHO in March 2020 producing deleterious effects on patients worldwide. The angiotensin-converting enzyme-2 (ACE-2) has been recognized as the coreceptor for SARS-CoV-2 infections and may act as a therapeutic step in blocking the enzyme to reduce SARS-CoV-2 expression and further cellular entry. Presently, the role of ACE-2 in coronavirus disease 2019 (COVID-19) infection has been known and the experts have started working on the enzyme ACE-2 for the management and treatment of this pandemic disease. The binding of spike (S) protein of SARS-CoV-2 to these receptors is the most important step and plays a key role in viral replication, thus this enzyme is becoming the doorway for the entry and spread in the human body causing asymptomatic pneumonia and severe of which is leading to death. As no specific method to prevent and treat this disease is available, the use of ACE-2 as a targeting ligand with COVID-19 virus spike protein could be helpful in the proper management of SARS-CoV-2 pneumonia.
Export Options
About this article
Cite this article as:
Pandey Vikas , Kanwar Lata Indu , Haider Tanweer, Gour Vishal , Vishwakarma Monika , Bakshi Kumar Avijit , Yadav Ravishankar and Soni Vandana*, Angiotensin Converting Enzyme-2: A Doorway for SARS-CoV-2, Coronaviruses 2021; 2 (12) : e070921191639 . https://dx.doi.org/10.2174/2666796702666210222110044
DOI https://dx.doi.org/10.2174/2666796702666210222110044 |
Print ISSN 2666-7967 |
Publisher Name Bentham Science Publisher |
Online ISSN 2666-7975 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
RNAi in Clinical Studies
Current Medicinal Chemistry Post-translational Modifications of Proteins: Biomarkers and Therapeutic Targets for Diabetes Related Complications
Current Proteomics The Pleiotropic Effects of Inducible Nitric Oxide Synthase (iNOS) on the Physiology and Pathology of Penile Erection
Current Pharmaceutical Design Therapeutic Potential of Janus Kinase 3 (JAK3) Inhibitors
Current Pharmaceutical Design Short and Long Term Effects of a DPP-4 Inhibitor Versus Bedtime NPH Insulin as ADD-ON Therapy in Patients with Type 2 Diabetes
Current Pharmaceutical Design Role of Resistin in Insulin Sensitivity in Rodents and Humans
Current Protein & Peptide Science The Importance of Reendothelialization After Arterial Injury
Current Pharmaceutical Design Editorial (Thematic Issue: “An Overview on Proteins of Biomedical Importance in Targeted Therapy of Cancer, Duchenne Muscular Dystrophy and Protein Misfolding Associated Neuropathy: Structure Function Relationship, Mechanism of Action, Role of Small Molecule Antagonist and Future Perspective”)
Current Chemical Biology Newer Approaches to the Discovery of Glitazones
Mini-Reviews in Organic Chemistry Ovarian Granulosa Cell Tumor: A Clinicoradiologic Series with Literature Review
Current Medical Imaging Uric Acid and Diabetes: Is there a Link?
Current Pharmaceutical Design Stages of HIV Replication and Targets for Therapeutic Intervention
Current Topics in Medicinal Chemistry A High Burden of Ischemic Stroke in Regions of Eastern/Central Europe is Largely Due to Modifiable Risk Factors
Current Neurovascular Research Characterization of Optimized Functional-Complementary Dual Insulinotorpic Peptide rolGG
Current Pharmaceutical Biotechnology Insoluble Solids in Brazilian and Floridian Acai (Euterpe oleraceae Mart.)
The Natural Products Journal Combating Obesity by Targeting Nuclear Receptors
Current Medicinal Chemistry - Immunology, Endocrine & Metabolic Agents Indications, Implications and Applications of Renal Denervation. Have we Discovered Something new?
Current Hypertension Reviews Pharmacological Characteristics of Parenteral IGF-I Administration
Current Pharmaceutical Biotechnology ACE Inhibitor-Angiotensin Receptor Blocker Combinations: A Clinicians Perspective
Mini-Reviews in Medicinal Chemistry Current Pharmacological Approach to Restore Endothelial Dysfunction
Cardiovascular & Hematological Agents in Medicinal Chemistry